Paper Details

  1. Home
  2. Paper Details

Effects of Ibudilast on MRI Measures in the Phase 2 SPRINT-MS Study.

Author: , BermelRobert A, CoffeyChristopher S, FedlerJanel, FoxRobert J, GoebelChristopher, GoodmanAndrew D, KearneyMarianne, KlawiterEric C, KlingnerElizabeth, NaismithRobert T, NakamuraKunio, NarayananSridar, YankeyJon

Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, N.I.H., ExtramuralResearch funding provided by the NIH to external research institutions and researchers.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Ibudilast, a drug commonly used for asthma, was found to be ineffective at reducing new or enlarging T2 lesions or new T1 lesions in patients with progressive forms of multiple sclerosis (MS). However, ibudilast was associated with a reduction in gray matter atrophy. This suggests that ibudilast may affect markers associated with neurodegenerative processes, but not inflammatory processes, in patients with MS.
Paper Details　
Original Abstract of the Article :
OBJECTIVE: To determine whether ibudilast has an effect on brain volume and new lesions in progressive forms of multiple sclerosis (MS). METHODS: A randomized, placebo-controlled, blinded study evaluated ibudilast at a dose of up to 100 mg over 96 weeks in primary and secondary progressive MS. In t...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7905793/

データ提供：米国国立医学図書館（NLM）

Ibudilast and Multiple Sclerosis: A Search for Effective Therapies

Multiple sclerosis (MS) is a chronic neurological disorder that affects the central nervous system. This study examines the effects of ibudilast, a drug with anti-inflammatory properties, on brain volume and lesion development in progressive forms of MS. It's like exploring a desert landscape, seeking a way to halt the erosion of brain tissue and prevent the formation of new lesions.

Ibudilast: A Promising but Partial Solution

The study found that ibudilast treatment was associated with a reduction in gray matter atrophy, but did not significantly reduce the formation of new lesions. It's like finding a source of water that can help replenish a desert oasis, but not completely prevent the erosion of sand dunes.

Continued Research: A Search for a Cure

The study emphasizes the need for further research into the potential benefits of ibudilast for MS. It's like exploring different paths through the desert, seeking a more comprehensive solution to this complex condition.

Dr.Camel's Conclusion

This study reminds us that the journey to finding a cure for MS is ongoing. While ibudilast shows promise in addressing some aspects of the disease, further research is crucial to discover more effective therapies. It's like continuing to explore the desert, seeking out new sources of water and pathways to a healthier and more sustainable future.
Date :
  1. Date Completed 2021-02-09
  2. Date Revised 2022-01-27
Further Info :

Pubmed ID

33268562

DOI: Digital Object Identifier

PMC7905793

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.